



June 28, 2022

British Columbia Securities Commission
Ontario Securities Commission
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
Autorité des marchés financiers
The Manitoba Securities Commission
Financial and Consumer Services Commission (New Brunswick)
Nova Scotia Securities Commission
Office of the Superintendent of Securities, Prince Edward Island
Office of the Superintendent of Securities Service, Newfoundland and Labrador

Dear Sirs/Mesdames:

Re: Algernon Pharmaceuticals Inc.

In connection with the Prospectus Supplement dated June 28, 2022 to the Short Form Base Shelf Prospectus of Algernon Pharmaceuticals Inc. dated May 5, 2021, we consent to the reference to our name on page S-3, S-4, S-26, under the heading “Interest of Experts”, under the heading “Legal Matters” and our opinion under the heading “Eligibility for Investment” in the Prospectus Supplement.

We have read the Prospectus Supplement and have no reason to believe that there are any misrepresentations in the information contained therein that is derived from our opinion referred to therein or that is within our knowledge as a result of the services that we performed in connection with such opinion.

Yours truly,

“McMillan LLP”